The hepatitis B virus ribonuclease H as a drug target

Antiviral Research

Volumn 118, Issue , 2015, Pages 132-138

  Tavis, John E ^a   Lomonosova, Elena ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatitis B virus; Inhibitors; Reverse transcription; Ribonuclease H

Indexed keywords

ALPHA HYDROXYTROPOLONE INHIBITOR; AMINOCYANOTHIOPHENE; CYANOPYRAN; DIOXOBUTANOIC ACID; ELVITEGRAVIR; ENZYME INHIBITOR; HEPATITIS B VIRUS RIBONUCLEASE H; HEPATITIS B VIRUS RIBONUCLEASE H INHIBITOR; HYDROXYCHROMENONE; HYDROXYXANTHENONE; INTEGRASE INHIBITOR; N HYDROXYISOQUINOLINEDIONE; NAPTHYRIDINONE; NUCLEOTIDYLTRANSFERASE; RALTEGRAVIR; RIBONUCLEASE H; THIENOPYRIMIDINONE; UNCLASSIFIED DRUG; VIRUS ENZYME; ANTIVIRUS AGENT; VIRAL PROTEIN;

ANTIVIRAL THERAPY; DRUG ANALYSIS; DRUG DESIGN; DRUG TARGETING; HEPATITIS B; LOW THROUGHPUT SCREENING; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; REVIEW; SCREENING; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; DRUG EFFECTS; HEPATITIS B VIRUS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; PHYSIOLOGY; TRENDS;

DNA VIRUSES; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

ANTIVIRAL AGENTS; DRUG DISCOVERY; ENZYME INHIBITORS; HEPATITIS B VIRUS; HUMANS; RIBONUCLEASE H; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84927950089     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.04.002     Document Type: Review

References (87)

1. W.R. Addison, K.A. Walters, W.W. Wong, J.S. Wilson, D. Madej, L.D. Jewell, and D.L. Tyrrell Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication J. Virol. 76 2002 6356 6363
2. A. Agrawal, J. DeSoto, J.L. Fullagar, K. Maddali, S. Rostami, D.D. Richman, Y. Pommier, and S.M. Cohen Probing chelation motifs in HIV integrase inhibitors Proc. Natl. Acad. Sci. U.S.A. 109 2012 2251 2256
3. A. Bertoletti, and A.J. Gehring Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control? PLoS Pathog. 9 2013 e1003784
4. M. Billamboz, F. Bailly, M.L. Barreca, L.L. De, J.F. Mouscadet, C. Calmels, M.L. Andreola, M. Witvrouw, F. Christ, Z. Debyser, and P. Cotelle Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain J. Med. Chem. 51 2008 7717 7730
5. M. Billamboz, F. Bailly, C. Lion, N. Touati, H. Vezin, C. Calmels, M.L. Andreola, F. Christ, Z. Debyser, and P. Cotelle Magnesium chelating 2-hydroxyisoquinoline-1,3(2H,4H)-diones, as inhibitors of HIV-1 integrase and/or the HIV-1 reverse transcriptase ribonuclease H domain: discovery of a novel selective inhibitor of the ribonuclease H function J. Med. Chem. 54 2011 1812 1824
6. T.M. Block, R. Gish, H. Guo, A. Mehta, A. Cuconati, W. Thomas London, and J.T. Guo Chronic hepatitis B: What should be the goal for new therapies? Antiviral Res. 98 2013 27 34
7. S.R. Budihas, I. Gorshkova, S. Gaidamakov, A. Wamiru, M.K. Bona, M.A. Parniak, R.J. Crouch, J.B. McMahon, J.A. Beutler, and S.F. Le Grice Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones Nucleic Acids Res. 33 2005 1249 1256
8. C.W. Cai, E. Lomonosova, E.A. Moran, X. Cheng, K.B. Patel, F. Bailly, P. Cotelle, M.J. Meyers, and J.E. Tavis Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity Antiviral Res. 108 2014 48 55
9. D. Cai, C. Mills, W. Yu, R. Yan, C.E. Aldrich, J.R. Saputelli, W.S. Mason, X. Xu, J.T. Guo, T.M. Block, A. Cuconati, and H. Guo Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation Antimicrob. Agents Chemother. 56 2012 4277 4288
10. L. Cao, W. Song, E. De Clercq, P. Zhan, and X. Liu Recent progress in the research of small molecule HIV-1 RNase H inhibitors Curr. Med. Chem. 21 2014 1956 1967
11. L.J. Chang, R.C. Hirsch, D. Ganem, and H.E. Varmus Effects of insertional and point mutations on the functions of the duck hepatitis B virus polymerase J. Virol. 64 1990 5553 5558
12. Y. Chen, and P.L. Marion Amino acids essential for RNAse H activity of hepadnaviruses are also required for efficient elongation of minus-strand DNA J. Virol. 70 1996 6151 6156
13. P.N. Cheng, W.C. Liu, H.W. Tsai, I.C. Wu, T.T. Chang, and K.C. Young Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents J. Med. Virol. 83 2011 602 607
14. J. Choi, E.E. Kim, Y.I. Park, and Y.S. Han Expression of the active human and duck hepatitis B virus polymerases in heterologous system of Pichia methanolica Antiviral Res. 55 2002 279 290
15. S. Chung, D.M. Himmel, J.K. Jiang, K. Wojtak, J.D. Bauman, J.W. Rausch, J.A. Wilson, J.A. Beutler, C.J. Thomas, E. Arnold, and S.F. Le Grice Synthesis, activity, and structural analysis of novel alpha-hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H J. Med. Chem. 54 2011 4462 4473
16. C.S. Coffin, P.M. Mulrooney-Cousins, M.G. Peters, M.G. van, J.P. Roberts, T.I. Michalak, and N.A. Terrault Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy J. Viral Hepat. 18 2011 415 423
17. N. Cox, and H. Tillmann Emerging pipeline drugs for hepatitis B infection Expert. Opin. Emerg. Drugs 16 2011 713 729
18. M. Dandri, M. Lutgehetmann, T. Volz, and J. Petersen Small animal model systems for studying hepatitis B virus replication and pathogenesis Semin. Liver Dis. 26 2006 181 191
19. M. Dandri, T.K. Volz, M. Lutgehetmann, and J. Petersen Animal models for the study of HBV replication and its variants J. Clin. Virol. 34 Suppl 1 2005 S54 S62
20. J. Didierjean, C. Isel, F. Querre, J.F. Mouscadet, A.M. Aubertin, J.Y. Valnot, S.R. Piettre, and R. Marquet Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H, and integrase activities by hydroxytropolones Antimicrob. Agents Chemother. 49 2005 4884 4894
21. J.L. Dienstag Benefits and risks of nucleoside analog therapy for hepatitis B Hepatology 49 2009 S112 S121
22. F. Dyda, A.B. Hickman, T.M. Jenkins, A. Engelman, R. Craigie, and D.R. Davies Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases Science 266 1994 1981 1986
23. A.S. Espeseth, P. Felock, A. Wolfe, M. Witmer, J. Grobler, N. Anthony, M. Egbertson, J.Y. Melamed, S. Young, T. Hamill, J.L. Cole, and D.J. Hazuda HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase Proc. Natl. Acad. Sci. U.S.A. 97 2000 11244 11249
24. F. Esposito, and E. Tramontano Past and future. Current drugs targeting HIV-1 integrase and reverse transcriptase-associated ribonuclease H activity: single and dual active site inhibitors Antiviral Chem. Chemother. 23 2014 129 144
25. E.O. Freed, and M.A. Martin HIVs and their replication D.M. Knipe, P.M. Howley, D.E. Griffin, R.A. Lamb, M.A. Martin, B. Roizman, S.E. Straus, Fields Virology 2007 Lippincott Williams & Wilkins Philadelphia 2107 2185
26. A. Gehring, A. Bertoletti, and J.E. Tavis Host factor-targeted hepatitis B virus therapies Intervirology 57 2014 158 162
27. T. Gerelsaikhan, J.E. Tavis, and V. Bruss Hepatitis B virus nucleocapsid envelopment does not occur without genomic DNA synthesis J. Virol. 70 1996 4269 4274
28. M. Ghany, and T.J. Liang Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B Gastroenterology 132 2007 1574 1585
29. Y. Gong, E. Yao, and J.E. Tavis Evidence that the RNAseH activity of the duck hepatitis B virus is unable to act on exogenous substrates BMC Microbiol. 1 2001 12
30. H. Guo, D. Jiang, T. Zhou, A. Cuconati, T.M. Block, and J.T. Guo Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation J. Virol. 81 2007 12472 12484
31. S. Hare, S.S. Gupta, E. Valkov, A. Engelman, and P. Cherepanov Retroviral intasome assembly and inhibition of DNA strand transfer Nature 464 2010 232 236
32. S. Hare, G.N. Maertens, and P. Cherepanov 3'-Processing and strand transfer catalysed by retroviral integrase in crystallo EMBO J. 31 2012 3020 3028
33. J. Hayer, C. Rodriguez, G. Germanidis, G. Deleage, F. Zoulim, J.M. Pawlotsky, and C. Combet Ultradeep pyrosequencing and molecular modeling identify key structural features of hepatitis B virus RNase H, a putative target for antiviral intervention J. Virol. 88 2014 574 582
34. D. Hazuda, M. Iwamoto, and L. Wenning Emerging pharmacology: inhibitors of human immunodeficiency virus integration Annu. Rev. Pharmacol. Toxicol. 49 2009 377 394
35. D.M. Himmel, S.G. Sarafianos, S. Dharmasena, M.M. Hossain, K. Coy-Simandle, T. Ilina, A.D. Clark Jr.; J.L. Knight, J.G. Julias, P.K. Clark, K. Krogh-Jespersen, R.M. Levy, S.H. Hughes, M.A. Parniak, and E. Arnold HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site ACS Chem. Biol. 1 2006 702 712
36. D.R. Hirsch, G. Cox, M.P. D'Erasmo, T. Shakya, C. Meck, N. Mohd, G.D. Wright, and R.P. Murelli Inhibition of the ANT(2'')-Ia resistance enzyme and rescue of aminoglycoside antibiotic activity by synthetic alpha-hydroxytropolones Bioorg. Med. Chem. Lett. 24 2014 4943 4947
37. Z. Hostomsky, Z. Hostomska, and D.A. Matthews Ribonuclease H S.M. Linn, R.S. Lloyd, R.J. Roberts, Nulceases 1993 Cold Spring Harbor Laboratory Press Plainview, NY 341 376
38. Y. Hu, X. Cheng, F. Cao, A. Huang, and J.E. Tavis Beta-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity Antiviral Res. 99 2013 221 229
39. K. Katayanagi, M. Miyagawa, M. Matsushima, M. Ishikawa, S. Kanaya, M. Ikehara, T. Matsuzaki, and K. Morikawa Three-dimensional structure of ribonuclease H from E. coli Nature 347 1990 306 309
40. Y.E. Khudyakov, and A.M. Makhov Prediction of terminal protein and ribonuclease H domains in the gene P product of hepadnaviruses FEBS Lett. 243 1989 115 118
41. T.A. Kirschberg, M. Balakrishnan, N.H. Squires, T. Barnes, K.M. Brendza, X. Chen, E.J. Eisenberg, W. Jin, N. Kutty, S. Leavitt, A. Liclican, Q. Liu, X. Liu, J. Mak, J.K. Perry, M. Wang, W.J. Watkins, and E.B. Lansdon RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information J. Med. Chem. 52 2009 5781 5784
42. G.J. Klarmann, M.E. Hawkins, and S.F. Le Grice Uncovering the complexities of retroviral ribonuclease H reveals its potential as a therapeutic target AIDS Rev. 4 2002 183 194
43. K. Klumpp, J.Q. Hang, S. Rajendran, Y. Yang, A. Derosier, K.I. Wong, H. Overton, K.E. Parkes, N. Cammack, and J.A. Martin Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors Nucleic Acids Res. 31 2003 6852 6859
44. K. Klumpp, and T. Mirzadegan Recent progress in the design of small molecule inhibitors of HIV RNase H Curr. Pharm. Des. 12 2006 1909 1922
45. H. Kwon, and A.S. Lok Hepatitis B therapy Nat. Rev. Gastroenterol. Hepatol. 8 2011 275 284
46. L. Lai, H. Yokota, L.W. Hung, R. Kim, and S.H. Kim Crystal structure of archaeal RNase HII: a homologue of human major RNase H Structure 8 2000 897 904
47. D. Lavanchy Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 34 Suppl 1 2005 S1 S3
48. S.F. Le Grice Human immunodeficiency virus reverse transcriptase: 25 years of research, drug discovery, and promise J. Biol. Chem. 287 2012 40850 40857
49. Y.I. Lee, Y.B. Hong, Y. Kim, H.M. Rho, and G. Jung RNase H activity of human hepatitis B virus polymerase expressed in Escherichia coli Biochem. Biophys. Res. Commun. 233 1997 401 407
50. Y. Li, S. Xuan, Y. Feng, and A. Yan Targeting HIV-1 integrase with strand transfer inhibitors Drug Discov. Today Dec. 6 2014 S1359 S6446
51. Y.F. Liaw Impact of therapy on the outcome of chronic hepatitis B Liver international: official journal of the International Association for the Study of the Liver 33 Suppl 1 2013 111 115
52. W.F. Lima, H. Wu, and S.T. Crooke Human RNases H Methods Enzymol. 341 2001 430 440
53. G. Lu, E. Lomonosova, X. Cheng, E.A. Moran, M.J. Meyers, S.F. Le Grice, C.J. Thomas, J.K. Jiang, C. Meck, D.R. Hirsch, M.P. D'Erasmo, D.M. Suyabatmaz, R.P. Murelli, and J.E. Tavis Hydroxylated tropolones inhibit hepatitis b virus replication by blocking the viral ribonuclease H activity Antimicrob. Agents Chemother. 59 2015 1070 1079
54. Y.Y. Lui, K.K. Tsoi, V.W. Wong, J.H. Kao, J.L. Hou, E.K. Teo, R. Mohamed, T. Piratvisuth, K.H. Han, U. Mihm, G.L. Wong, and H.L. Chan Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy Antivir. Ther. 15 2010 145 155
55. P. Marcellin, and T. Asselah Viral hepatitis: impressive advances but still a long way to eradication of the disease Liver Int. 34 Suppl. 1 2014 1 3
56. C. Meck, M.P. D'Erasmo, D.R. Hirsch, and R.P. Murelli The biology and synthesis of alpha-hydroxytropolones MedChemComm 5 2014 842 852
57. C. Meck, N. Mohd, and R.P. Murelli An oxidopyrylium cyclization/ring-opening route to polysubstituted alpha-hydroxytropolones Org. Lett. 14 2012 5988 5991
58. T. Mesplede, P.K. Quashie, V. Zanichelli, and M.A. Wainberg Integrase strand transfer inhibitors in the management of HIV-positive individuals Ann. Med. 46 2014 123 129
59. A. Monto, R.T. Schooley, J.C. Lai, M.S. Sulkowski, R.T. Chung, J.M. Pawlotsky, J.G. McHutchison, and I.M. Jacobson Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop Am. J. Gastroenterol. 105 2010 989 1004
60. G. Moraleda, J. Saputelli, C.E. Aldrich, D. Averett, L. Condreay, and W.S. Mason Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus J. Virol. 71 1997 9392 9399
61. M. Nowotny Retroviral integrase superfamily: the structural perspective EMBO Rep. 10 2009 144 151
62. M. Nowotny, S.A. Gaidamakov, R.J. Crouch, and W. Yang Crystal structures of RNase H bound to an RNA/DNA hybrid: substrate specificity and metal-dependent catalysis Cell 121 2005 1005 1016
63. M. Nowotny, and W. Yang Stepwise analyses of metal ions in RNase H catalysis from substrate destabilization to product release EMBO J. 25 2006 1924 1933
64. N. Potenza, V. Salvatore, D. Raimondo, D. Falanga, V. Nobile, D.L. Peterson, and A. Russo Optimized expression from a synthetic gene of an untagged RNase H domain of human hepatitis B virus polymerase which is enzymatically active Protein Expr. Purif. 55 2007 93 99
65. G. Radziwill, W. Tucker, and H. Schaller Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity J. Virol. 64 1990 613 620
66. S. Schaefer Hepatitis B virus taxonomy and hepatitis B virus genotypes World J. Gastroenterol. 13 2007 14 21
67. F. Schodel, T. Weimer, H. Will, and R. Sprengel Amino acid sequence similarity between retroviral and E. coli RNase H and hepadnaviral gene products AIDS Res. Hum. Retroviruses 4 1988 9 11
68. C. Seeger, F. Zoulim, and W.S. Mason Hepadnaviruses D.M. Knipe, P.M. Howley, Fields Virology 6 ed. 2013 Lippincott Williams & Wilkins Philadelphia PA 2185 2221
69. M.F. Sorrell, E.A. Belongia, J. Costa, I.F. Gareen, J.L. Grem, J.M. Inadomi, E.R. Kern, J.A. McHugh, G.M. Petersen, M.F. Rein, D.B. Strader, and H.T. Trotter National institutes of health consensus development conference statement: management of hepatitis B Ann. Intern. Med. 150 2009 104 110
70. H.P. Su, Y. Yan, G.S. Prasad, R.F. Smith, C.L. Daniels, P.D. Abeywickrema, J.C. Reid, H.M. Loughran, M. Kornienko, S. Sharma, J.A. Grobler, B. Xu, V. Sardana, T.J. Allison, P.D. Williams, P.L. Darke, D.J. Hazuda, and S. Munshi Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors J. Virol. 84 2010 7625 7633
71. J. Summers, and W.S. Mason Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate Cell 29 1982 403 415
72. Tavis, J.E.; Badtke, M.P.; 2009. Hepadnaviral Genomic Replication, in: Cameron, C.E.; Götte, M.; Raney, K.D. (Eds.), Viral Genome Replication. Springer Science+Business Media, LLC, New York, pp. 129-143.
73. J.E. Tavis, X. Cheng, Y. Hu, M. Totten, F. Cao, E. Michailidis, R. Aurora, M.J. Meyers, E.J. Jacobsen, M.A. Parniak, and S.G. Sarafianos The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes PLoS Pathog. 9 2013 e1003125
74. J.E. Tavis, H. Wang, A.E. Tollefson, B. Ying, M. Korom, X. Cheng, F. Cao, K.L. Davis, W.S. Wold, and L.A. Morrison Inhibitors of nucleotidyl transferase superfamily enzymes suppress herpes simplex virus replication Antimicrob. Agents Chemother. 58 2014 7451 7461
75. F. van Bommel, R.A. De Man, H. Wedemeyer, K. Deterding, J. Petersen, P. Buggisch, A. Erhardt, D. Huppe, K. Stein, J. Trojan, C. Sarrazin, W.O. Bocher, U. Spengler, H.E. Wasmuth, J.G. Reinders, B. Moller, P. Rhode, H.H. Feucht, B. Wiedenmann, and T. Berg Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues Hepatology 51 2010 73 80
76. X. Wei, and D.L. Peterson Expression, purification, and characterization of an active RNase H domain of the hepatitis B viral polymerase J. Biol. Chem. 271 1996 32617 32622
77. Y. Wei, J.E. Tavis, and D. Ganem Relationship between viral DNA synthesis and virion envelopment in hepatitis B viruses J. Virol. 70 1996 6455 6458
78. B. Werle-Lapostolle, S. Bowden, S. Locarnini, K. Wursthorn, J. Petersen, G. Lau, C. Trepo, P. Marcellin, Z. Goodman, W.E. Delaney, S. Xiong, C.L. Brosgart, S.S. Chen, C.S. Gibbs, and F. Zoulim Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy Gastroenterology 126 2004 1750 1758
79. P.D. Williams, D.D. Staas, S. Venkatraman, H.M. Loughran, R.D. Ruzek, T.M. Booth, T.A. Lyle, J.S. Wai, J.P. Vacca, B.P. Feuston, L.T. Ecto, J.A. Flynn, D.J. DiStefano, D.J. Hazuda, C.M. Bahnck, A.L. Himmelberger, G. Dornadula, R.C. Hrin, K.A. Stillmock, M.V. Witmer, M.D. Miller, and J.A. Grobler Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffold Bioorg. Med. Chem. Lett. 20 2010 6754 6757
80. Y.D. Williams, C. Meck, N. Mohd, and R.P. Murelli Triflic acid-mediated rearrangements of 3-methoxy-8-oxabicyclo[3.2.1]octa-3,6-dien-2-ones: synthesis of methoxytropolones and furans J. Org. Chem. 78 2013 11707 11713
81. D.K. Wong, M.F. Yuen, V.W. Ngai, J. Fung, and C.L. Lai One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels Antivir. Ther. 11 2006 909 916
82. G. Woo, G. Tomlinson, Y. Nishikawa, M. Kowgier, M. Sherman, D.K. Wong, B. Pham, W.J. Ungar, T.R. Einarson, E.J. Heathcote, and M. Krahn Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses Gastroenterology 139 2010 1218 1229
83. W. Yang, and T.A. Steitz Recombining the structures of HIV integrase, RuvC and RNase H Structure 3 1995 131 134
84. J. Zhao Plant troponoids: chemistry, biological activity, and biosynthesis Curr. Med. Chem. 14 2007 2597 2621
85. Y. Zhu, T. Yamamoto, J. Cullen, J. Saputelli, C.E. Aldrich, D.S. Miller, S. Litwin, P.A. Furman, A.R. Jilbert, and W.S. Mason Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis J. Virol. 75 2001 311 322
86. F. Zoulim Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 31 Suppl 1 2011 111 116
87. F. Zoulim, and S. Locarnini Hepatitis B virus resistance to nucleos(t)ide analogues Gastroenterology 137 2009 1593 1608